Medscape Special Report: FDA Nixes 3 Weight Loss Drugs
As obesity rates continue to rise, the need for a safe and effective weight loss drug is urgent… And yet, 3 promising therapies have been halted in the pipeline this past year. This special collection provides clinicians with a clear picture of the current state of weight loss pharmacotherapy.
— Christine Wiebe, Editorial Director, Medscape Diabetes & Endocrinology
FDA Declines Approval for Contrave Diet Drug; Asks for CVD Outcomes Studies
FDA Seeks Birth-Defect Data for Experimental Obesity Drug
FDA Rejects Qnexa, Asks for More Info
http://www.medscape.com/viewarticle/733585...
— Christine Wiebe, Editorial Director, Medscape Diabetes & Endocrinology
FDA Declines Approval for Contrave Diet Drug; Asks for CVD Outcomes Studies
FDA Seeks Birth-Defect Data for Experimental Obesity Drug
FDA Rejects Qnexa, Asks for More Info
http://www.medscape.com/viewarticle/733585...
